Mechanism of action of anti-TNF therapy in inflammatory bowel disease
AD Levin, ME Wildenberg… - Journal of Crohn's and …, 2016 - academic.oup.com
Several anti-tumour necrosis factor [TNF] blocking strategies have been evaluated in
patients with Crohn's disease. Compounds that have been tested included the full …
patients with Crohn's disease. Compounds that have been tested included the full …
Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-α Treatment—A Review
TNF-α inhibitors (TNFis) have revolutionized the treatment of certain chronic immune-
mediated diseases, being widely and successfully used in rheumatic inflammatory diseases …
mediated diseases, being widely and successfully used in rheumatic inflammatory diseases …
Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for …
J Korzenik, MD Larsen, J Nielsen… - Alimentary …, 2019 - Wiley Online Library
Background Anti‐TNFα agents have revolutionised management of chronic inflammatory
diseases. Paradoxically, these agents might provoke development of de novo autoimmune …
diseases. Paradoxically, these agents might provoke development of de novo autoimmune …
[HTML][HTML] Paradoxical reactions to biologicals in chronic inflammatory systemic diseases
I Kremenevski, O Sander, M Sticherling… - Deutsches Ärzteblatt …, 2022 - ncbi.nlm.nih.gov
Background Biological agents that contain substances affecting the immune system are
increasingly being used to treat chronic inflammatory systemic diseases. Aside from the …
increasingly being used to treat chronic inflammatory systemic diseases. Aside from the …
Inflammatory bowel disease provoked by etanercept: report of 443 possible cases combined from an IBD referral center and the FDA
A O'Toole, M Lucci, J Korzenik - Digestive diseases and sciences, 2016 - Springer
Background Anti-TNF therapies have revolutionized the treatment of autoimmune
inflammatory conditions. Paradoxical treatment with these agents is associated with the …
inflammatory conditions. Paradoxical treatment with these agents is associated with the …
drug‐induced small bowel injury
Background Drug‐induced gastrointestinal injury has been increasingly reported, but its
exact incidence is not known. The small and large intestines represent the most affected …
exact incidence is not known. The small and large intestines represent the most affected …
Repurposing haloperidol for the treatment of rheumatoid arthritis: an integrative approach using data mining techniques
C Nakagawa, S Yokoyama… - Therapeutic …, 2021 - journals.sagepub.com
Introduction: Treatment of rheumatoid arthritis (RA) has advanced with the introduction of
biological disease-modifying antirheumatic drugs. However, more than 20% of patients with …
biological disease-modifying antirheumatic drugs. However, more than 20% of patients with …
Antitumor necrosis factor-α therapy associated with inflammatory bowel disease: three cases and a systematic literature review
A Bieber, A Fawaz, I Novofastovski… - The Journal of …, 2017 - jrheum.org
Objective. Antitumor necrosis factor-α (anti-TNF-α) therapy is the most prescribed biologic
agent therapy in rheumatology and gastroenterology. However, a number of serious side …
agent therapy in rheumatology and gastroenterology. However, a number of serious side …
Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real‐World Assessment
ZQ Zhan, JX Li, YX Chen… - United European …, 2024 - Wiley Online Library
ABSTRACT Background and Objective With limited evidence connecting paradoxical
inflammatory bowel disease (paradoxical IBD) to the newest biologics and Janus kinase …
inflammatory bowel disease (paradoxical IBD) to the newest biologics and Janus kinase …
Real-world individual and comparative analysis of adverse event reporting for adalimumab and etanercept using public FDA adverse event reporting system data
X Dou, Y Dai, L Zhu, Y Lin, Y Wu - Archives of Dermatological Research, 2024 - Springer
Objective We analyzed adverse events (AEs) related to adalimumab and etanercept using
the Food and Drug Administration Adverse Event Reporting System (FAERS) to detect …
the Food and Drug Administration Adverse Event Reporting System (FAERS) to detect …